Christine Hamolia
Clinical Nurse Specialist · Charleston, SCNPI 1902914856
Payments from drug & device makers
Across 240 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$598
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$446
- Otsuka America Pharmaceutical, Inc.$445
- Supernus Pharmaceuticals, Inc.$437
- Sunovion Pharmaceuticals Inc.$358
- Johnson & Johnson$294
- plus $2K from 18 others
What the payments were for
- Food & beverage$4,91999%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 45 | $598 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $446 |
| Otsuka America Pharmaceutical, Inc. | 25 | $445 |
| Supernus Pharmaceuticals, Inc. | 14 | $437 |
| Sunovion Pharmaceuticals Inc. | 16 | $358 |
| Johnson & Johnson | 14 | $294 |
| Lundbeck LLC | 15 | $290 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $280 |
| Corium, LLC | 10 | $244 |
| E.r. Squibb & Sons, L.L.C. | 5 | $232 |
| Vanda Pharmaceuticals Inc. | 9 | $228 |
| Axsome Therapeutics, Inc. | 10 | $217 |
| Alkermes, Inc. | 10 | $203 |
| Neurocrine Biosciences, Inc. | 7 | $175 |
| Teva Pharmaceuticals USA, Inc. | 6 | $158 |
| Merck | 5 | $80 |
| Idorsia Pharmaceuticals US Inc | 4 | $75 |
| Livanova USA, Inc. | 3 | $56 |
| Tris Pharma Inc | 2 | $38 |
| Jazz Pharmaceuticals Inc. | 2 | $34 |
| Eisai Inc. | 2 | $29 |
| Almatica Pharma LLC | 1 | $17 |
| Neos Therapeutics, LP | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few clinical nurse specialist providers in South Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $97,179 |
| SpravatoEsketamine Hcl | 16 | $55,536 |
| VraylarCariprazine Hcl | 26 | $36,078 |
| CaplytaLumateperone Tosylate | 12 | $20,146 |
| BelsomraSuvorexant | 23 | $9,954 |
| VyvanseLisdexamfetamine Dimesylate | 17 | $6,498 |
| Lisdexamfetamine Dimesylate | 12 | $2,139 |
| Bupropion XlBupropion Hcl | 80 | $1,845 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 69 | $1,761 |
| Duloxetine Hcl | 84 | $1,735 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 37 | $1,698 |
| Quetiapine Fumarate | 90 | $1,441 |
| Trazodone Hcl | 99 | $1,012 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 49 | $837 |
| Lurasidone Hcl | 23 | $786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $175 | $97,17912 claims |
| Johnson & JohnsonSpravato | $294 | $55,53616 claims |
| AbbVieVraylar | $598 | $36,07826 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $446 | $20,14612 claims |
| MerckBelsomra | $80 | $9,95423 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $280 | $6,49817 claims |
| Almatica Pharma LLCSertraline Hcl | $17 | $54586 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical nurse specialist providers in South Carolinaon file to place this against a meaningful peer group, so we don't.
Other clinical nurse specialist in Charleston
- Teresa KelechiCharleston$401
- Carol BurnsCharleston$29
- Amy KingMount Pleasant$552
- Carla JohnsonSalters$36
- Bonnie WalkerGreenville$19
- Donna AmbroseGreenville$12
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.